Synergy enjoys Phase IIb/III success for chronic constipation drug
This article was originally published in Scrip
Executive Summary
Synergy Pharmaceuticals is considering the next developmental steps for its lead drug candidate, plecanatide, for chronic idiopathic constipation (CIC) after top-line data showed that the product met the primary and "key" secondary endpoints in a Phase IIb/III study.